The Lynx Group

Web Exclusives

Conquer Cancer Foundation of ASCO & Swim Across America Team Up To Create Young Investigator Award
Web Exclusives — February 19, 2019
Swim Across America is supporting the American Society of Clinical Oncology (ASCO) and ASCO’s Conquer Cancer Foundation with the creation of the Conquer Cancer Foundation of ASCO—Swim Across America Young Investigator Award (YIA).
Read Article


Web Exclusives — February 1, 2019
San Diego, CA—In patients with multiple myeloma (MM), the use of drug therapy as maintenance has been shown to prolong the length of time the disease is controlled. Specifically, use of maintenance therapy may affect overall survival, particularly when it is used after an autologous stem-cell transplant (ASCT).
Read Article


Web Exclusives — January 14, 2019
Now in its fourth week, the longest shutdown in the history of the federal government is having an impact on patient care, as the US Food and Drug Administration (FDA) has put drug reviews and approvals for new drugs and devices, as well as the issuance of new guidance documents, on indefinite hold. The FDA recently posted on its website a notice alerting the public of its current operational status.
Read Article

Web Exclusives — August 28, 2018
Once-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress.
Read Article

Web Exclusives — August 20, 2018
San Francisco, CA—Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis.
Read Article


Web Exclusives — July 31, 2018
Experts at this roundtable discussion addressed high patient costs, achieving greater value in oncology care, and the desire for access to comparative data.
Read Article

Web Exclusives — July 24, 2018
On February 14, 2018, apalu­tamide (Erleada; Janssen Pharmaceuticals), an androgen receptor inhibitor, received accelerated approval by the FDA for the treatment of patients with nonmetastatic, cas­tration-resistant prostate cancer (CRPC). Apalutamide is the first treatment approved by the FDA for patients with nonmetastatic CRPC, and was approved under the FDA priority review process.
Read Article

Page 7 of 9

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: